NEW YORK (GenomeWeb News) – Molecular diagnostics firm Satoris today said that it has been appointed global distributor for Rules-Based Medicine's DiscoveryMAP panel for neurology research.
The RBM DisocveryMAP is a 189-biomarker panel that covers the most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development, said Redwood City, Calif.-based Satoris in a statement.
Cris McReynolds, president and CEO of Satoris, said that the RBM panel "will be an important tool in accelerating research on Alzheimer's disease and related neurodegenerative disorders."
Satoris noted that in June it launched three of its own biomarker panels including a Dementia Discrimination panel, which the firm said is used to differentiate Alzheimer's patients from patients with other forms of dementia. It also introduced its Neuro61 and Neuro77 panels to identify plasma proteins associated with neurodegeneration and neuroinflammation.
Financial and other terms of the agreement with Austin, Texas-based RBM were not disclosed.